AR051698A1 - Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa - Google Patents
Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasaInfo
- Publication number
- AR051698A1 AR051698A1 ARP050105071A ARP050105071A AR051698A1 AR 051698 A1 AR051698 A1 AR 051698A1 AR P050105071 A ARP050105071 A AR P050105071A AR P050105071 A ARP050105071 A AR P050105071A AR 051698 A1 AR051698 A1 AR 051698A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- alkyl
- optionally substituted
- incorporates
- optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Junto con procesos para su preparacion, composiciones que ,los contienen y su uso terapéutico. Los compuesto son inhibidores de la enzima MPO y, por ello, son particularmente utiles en el tratamiento o la prevencion de trastornos neuroinflamatorios, trastornos cardiovasculares. Reivindicacion 1: Un compuesto de la formula (1) donde al menos uno de X e Y representa S y el otro representa O o S; L representa un enlace directo o alquileno C1-7, donde dicho alquileno incorpora opcionalmente un heteroátomo seleccionado de O, S(O)n y NR6 y dicho alquileno incorpora opcionalmente 1 o 2 enlaces dobles C-C, y dicho alquileno está opcionalmente sustituido con uno o varios sustituyentes seleccionados, de modo independiente, de OH, halogeno, CN y NR4R5, alquilo C1-6 y alcoxi C1-6, donde dicho alcoxi incorpora opcionalmente un carbonilo adyacente al O; n representa un numero entero 0, 1, o 2; R1 representa H o i) un anillo saturado o parcialmente insaturado de 3 a 7 miembros que opcionalmente incorpora 1 o 2 heteroátomos seleccionados, de modo independiente, de O, N y S, y que opcionalmente incorpora un grupo carbonilo, opcionalmente sustituido con 1 o varios sustituyentes seleccionados de halogeno, SO2R9, SO2NR9R10, OH, alquilo C1-7, alcoxi C1-7, CN, CONR2R3, NR2COR3 y COE3, donde dicho alcoxi está también opcionalmente sustituido con alcoxi C1-6 y donde dicho alcoxi incorpora opcionalmente un carbonilo adyacente al O y dicho alquilo está también opcionalmente sustituido con hidroxi o alcoxi C1-6 y dicho alquilo o alcoxi incorpora opcionalmente un carbonilo adyacente al O o en cualquier posicion en el anillo o ii) un sistema de anillos aromáticos seleccionado de fenilo, bifenilo, naftilo o una estructura de anillo heteroaromática monocíclica o bicíclica que contiene 1 a 3 heteroátomos seleccionados, de modo independiente, de O, N y S, donde dicho sistema e anillo aromático está opcionalmente sustituido con 1 o varios sustituyentes seleccionados de halogeno, SO2R9, SO2NR9R10, OH, alquilo C1-7, alcoxi C1-7, CN, CONR2R3, NR2COR3 y COR3; donde dicho alcoxi está también opcionalmente sustituido con alcoxi C1-6 y donde dicho alcoxi incorpora opcionalmente un carbonilo adyacente al O y dicho alquilo está también opcionalmente sustituido con hidroxi o alcoxi C1-6 y dicho alquilo o alcoxi incorpora un carbonilo adyacente al O o en cualquier posicion en el alquilo; R12 representa H o halogeno o un C opcionalmente sustituido con 1 a 3 átomos de halogeno; en cada aparicion R2, R3, R4, R5, R6, R9 y R10 representan, de modo independiente, H, alquilo C1-6 o alcoxi C1-6 donde dicho alcoxi incorpora un carbonilo adyacente al O, y dicho alquilo está también opcionalmente sustituido con halogeno, alcoxi C1-6, CHO, alcanoílo C2-6, OH, CONR7R8 y NR7COR8; o los grupos NR2R3, NR4R5 y NR9R10 representan cada uno, de modo independiente, un anillo azacíclico saturado e 5 a 7 miembros que opcionalmente incorpora un heteroátomo adicional seleccionado de O, S y NR11, donde dicho anillo está también opcionalmente sustituido con halogeno, alcoxi C1-6, CHO, alcanoílo C2-6, OH, CONR7R8 y NR7COR8; en cada aparicion R7, R8 y R11 representan, de modo independiente, H o alquilo C1-6, o el grupo NR7R8 representa un anillo azacíclico saturado de 5 a 7 miembros que opcionalmente incorpora un heteroátomo adicional seleccionado de O, S y NR11; y sus sales farmacéuticamente aceptables; con la condicion de que se excluyan los compuestos 1-beta-D- ribofuranosil-2-oxopirrolo[3,2-d]pirimidin-4(3H,5H)-tiona, 1-(2,3,5-tri-O-benzoil-1-beta-D-ribofuranosil)-2-oxopirrolo[3,2-d]pirimidin-4(3H,5H)-tiona y 5,7-dimercapto-1,4,6-triazaindeno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0402972A SE0402972D0 (sv) | 2004-12-06 | 2004-12-06 | Novel compounds |
| SE0501093 | 2005-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051698A1 true AR051698A1 (es) | 2007-01-31 |
Family
ID=36578191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105071A AR051698A1 (es) | 2004-12-06 | 2005-12-05 | Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US7829707B2 (es) |
| EP (1) | EP1824855B1 (es) |
| JP (1) | JP5028270B2 (es) |
| KR (3) | KR101412786B1 (es) |
| CN (1) | CN101072778B (es) |
| AR (1) | AR051698A1 (es) |
| AU (1) | AU2005312388B2 (es) |
| BR (1) | BRPI0518846B1 (es) |
| CA (1) | CA2591314C (es) |
| CY (1) | CY1113209T1 (es) |
| DK (1) | DK1824855T3 (es) |
| ES (1) | ES2390888T3 (es) |
| HK (1) | HK1110859A1 (es) |
| HR (1) | HRP20120781T1 (es) |
| IL (1) | IL183182A (es) |
| ME (1) | ME01486B (es) |
| MX (1) | MX2007006497A (es) |
| MY (1) | MY140748A (es) |
| NO (1) | NO20072399L (es) |
| NZ (1) | NZ555046A (es) |
| PL (1) | PL1824855T3 (es) |
| PT (1) | PT1824855E (es) |
| RS (1) | RS52490B (es) |
| RU (2) | RU2409578C2 (es) |
| SA (1) | SA05260385B1 (es) |
| SI (1) | SI1824855T1 (es) |
| TW (1) | TWI365189B (es) |
| UA (1) | UA89968C2 (es) |
| UY (1) | UY29246A1 (es) |
| WO (1) | WO2006062465A1 (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| CA2643235C (en) * | 2006-02-21 | 2014-06-17 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| US20090286813A1 (en) * | 2006-04-13 | 2009-11-19 | Astrazeneca Ab | Thioxanthine Derivatives and Their Use as Inhibitors of MPO |
| TW200806667A (en) * | 2006-04-13 | 2008-02-01 | Astrazeneca Ab | New compounds |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
| JP5201063B2 (ja) * | 2008-04-15 | 2013-06-05 | 信越化学工業株式会社 | 付加硬化型シリコーン組成物及びその硬化物 |
| AU2010227245B2 (en) | 2009-03-23 | 2015-09-10 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as TRPA1 modulators |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| TWI501967B (zh) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
| TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| TWI527814B (zh) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| MD20140044A2 (ro) | 2011-11-11 | 2014-08-31 | Pfizer Inc. | 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare |
| WO2013150115A1 (en) * | 2012-04-05 | 2013-10-10 | Basf Se | N- substituted hetero - bicyclic compounds and derivatives for combating animal pests |
| EA036592B1 (ru) | 2012-06-13 | 2020-11-26 | Инсайт Холдингс Корпорейшн | Замещенные трициклические соединения как ингибиторы fgfr |
| PT2864323T (pt) | 2012-06-15 | 2017-07-14 | Janssen Sciences Ireland Uc | Derivados de 1,3-di-hidro-2h-benzimidazol-2-ona substituídos com heterociclos como agentes antivirais do vírus sincicial respiratório |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| CN109912594A (zh) | 2013-04-19 | 2019-06-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
| EP3191485A1 (en) * | 2014-09-11 | 2017-07-19 | Bristol-Myers Squibb Company | Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9616063B2 (en) * | 2014-12-01 | 2017-04-11 | Astrazeneca Ab | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MA51229A (fr) | 2015-02-20 | 2021-03-24 | Incyte Corp | Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CN107531647A (zh) | 2015-05-05 | 2018-01-02 | 辉瑞大药厂 | 2‑硫代嘧啶酮类 |
| US10407422B2 (en) | 2015-09-03 | 2019-09-10 | Bristol-Myers Squibb Company | Triazolopyridine inhibitors of myeloperoxidase |
| WO2017040451A1 (en) * | 2015-09-03 | 2017-03-09 | Bristol-Myers Squibb Company | Triazolopyridine inhibitors of myeloperoxidase |
| US11059818B2 (en) * | 2016-03-14 | 2021-07-13 | Bristol-Myers Squibb Company | Triazolopyridine inhibitors of myeloperoxidase |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| AU2018304508B2 (en) * | 2017-07-17 | 2021-06-10 | Astrazeneca Ab | MPO inhibitors for use in medicine |
| US10781226B2 (en) | 2017-10-19 | 2020-09-22 | Texas State University | Photoactivatable cancer prodrug |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
| WO2020021300A1 (en) | 2018-07-24 | 2020-01-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of myeloperoxidase (mpo) inhibitors for the treatment of chemoresistant acute myeloid leukemia (aml) |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021013942A1 (en) | 2019-07-24 | 2021-01-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of myeloperoxidase inhibitors for the treatment of cardiovascular diseases in patients suffering from myeloproliferative neoplasms |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2021230370A1 (en) * | 2020-03-05 | 2022-10-20 | Biohaven Therapeutics Ltd. | Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor |
| US20230192700A1 (en) | 2020-03-06 | 2023-06-22 | Bayer Aktiengesellschaft | Pyrazolopyrazines acting on cancers via inhibition of cdk12 |
| IL297857A (en) * | 2020-05-06 | 2023-01-01 | Biohaven Therapeutics Ltd | A process for making verdiprestat |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| CN115403584B (zh) * | 2021-05-26 | 2024-04-02 | 长春金赛药业有限责任公司 | 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用 |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| WO2024038131A1 (en) | 2022-08-18 | 2024-02-22 | Astrazeneca Ab | Inhibitors of myeloperoxidase |
| WO2024120457A1 (zh) * | 2022-12-09 | 2024-06-13 | 深圳信立泰药业股份有限公司 | 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135753A (en) * | 1961-05-10 | 1964-06-02 | Burroughs Wellcome Co | Alkylthiopurines and method |
| US3652579A (en) * | 1969-06-26 | 1972-03-28 | Hoffmann La Roche | 1-methyl-2-substituted 5-nitroimidazoles |
| SE7810947L (sv) | 1978-10-20 | 1980-04-21 | Draco Ab | 3-alkylxanthines |
| US4710503A (en) * | 1985-02-07 | 1987-12-01 | Euroceltique S.A. | 6-thioxanthine derivatives |
| WO1989006125A1 (en) | 1987-12-31 | 1989-07-13 | Smithkline Beckman Corporation | 4-aralkyl-5-substituted-1,2,4-triazole-5-thiols |
| DK440989A (da) | 1988-09-12 | 1990-03-13 | Smithkline Beecham Corp | Dopamin-beta-hydroxylase inhibitorer |
| JPH02160235A (ja) | 1988-12-13 | 1990-06-20 | Konica Corp | ハロゲン化銀カラー写真画像の形成方法 |
| EP0430300A3 (en) | 1989-12-01 | 1992-03-25 | Takeda Chemical Industries, Ltd. | Xanthine derivatives, their production and use |
| US5100906A (en) | 1990-04-19 | 1992-03-31 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers |
| FR2665636B1 (fr) * | 1990-08-10 | 1994-10-07 | Adir | Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer. |
| US6046019A (en) * | 1991-07-09 | 2000-04-04 | Goumeniouk; Alexander P. | Diagnostic kits and methods for making granulocyte cell counts |
| US5281209A (en) | 1992-06-30 | 1994-01-25 | The Procter & Gamble Company | Absorbent article having tucked flaps |
| EP0638080A4 (en) | 1992-04-21 | 1995-08-23 | Biocryst Pharm Inc | PYRIMIDINE 7-BISUBSTITUEE-METHYL-4-OXO-3H -, 5H --PYRROLO 3,2-d -], PHARMACEUTICAL USE AND COMPOSITIONS CONTAINING SAID PYRIMIDINE. |
| US6469017B1 (en) | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| NZ274244A (en) * | 1993-11-26 | 1997-09-22 | Pfizer | Isoxazoline derivatives and medicaments |
| US5489598A (en) * | 1994-06-08 | 1996-02-06 | Warner-Lambert Company | Cytoprotection utilizing aryltriazol-3-thiones |
| US6066641A (en) * | 1994-12-13 | 2000-05-23 | Euro-Celtique S.A. | Aryl thioxanthines |
| US6025361A (en) * | 1994-12-13 | 2000-02-15 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
| WO1996018400A1 (en) * | 1994-12-13 | 1996-06-20 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
| US5756511A (en) * | 1995-04-03 | 1998-05-26 | Cell Therapeutics, Inc. | Method for treating symptoms of a neurodegenerative condition |
| US6294541B1 (en) * | 1996-06-06 | 2001-09-25 | Euro-Celtique S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
| GB9626643D0 (en) | 1996-12-21 | 1997-02-12 | Astra Pharma Prod | Compounds |
| US5976823A (en) * | 1997-03-19 | 1999-11-02 | Integrated Biomedical Technology, Inc. | Low range total available chlorine test strip |
| EP1016407B1 (en) | 1997-09-05 | 2006-05-10 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives for treating brain ischemia |
| WO1999014204A1 (en) | 1997-09-16 | 1999-03-25 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
| AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| US6319928B1 (en) * | 1998-11-30 | 2001-11-20 | Euro-Celtique, S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
| DZ3019A1 (fr) | 1999-03-01 | 2005-05-20 | Smithkline Beecham Corp | Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd. |
| HUP0200938A2 (en) | 1999-04-02 | 2002-10-28 | Euro Celtique Sa | Purine derivatives having phosphodiesterase iv inhibition activity and medicaments containing them |
| GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
| FR2811989A1 (fr) | 2000-07-18 | 2002-01-25 | Sanofi Synthelabo | Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique |
| EP1305328A2 (en) | 2000-07-21 | 2003-05-02 | Mark B. Lyles | Materials and methods for binding nucleic acids to surfaces |
| GB0100623D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
| GB0100620D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
| FR2819723B1 (fr) * | 2001-01-23 | 2006-11-17 | Arnaud Mainnemare | Composition halogene, son procede de preparation et ses utilisations |
| WO2002066447A1 (en) | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors |
| SE0103766D0 (sv) * | 2001-11-09 | 2001-11-09 | Astrazeneca Ab | Novel assay |
| WO2002090575A1 (en) | 2001-05-08 | 2002-11-14 | Astrazeneca Ab | An assay for detecting inhibitors of the enzyme mueloperokidase |
| ES2193839B1 (es) * | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| ES2686123T3 (es) | 2002-01-28 | 2018-10-16 | Kyowa Hakko Kogyo Co., Ltd | Antagonistas del receptor A2A para su uso en el tratamiento de trastornos del movimiento |
| ES2208063B1 (es) | 2002-04-01 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida. |
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| SE0301232D0 (sv) * | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
| SE0302756D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
| DE602004018808D1 (de) * | 2003-10-31 | 2009-02-12 | Cv Therapeutics Inc | Antagonisten des a2b-adenosinrezeptors |
| US7713982B2 (en) | 2004-02-14 | 2010-05-11 | Smithkline Beecham Corporation | Xanthines with HM74A receptor activity |
| WO2006045564A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
| SE0402591D0 (sv) | 2004-10-25 | 2004-10-25 | Astrazeneca Ab | Novel use |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| TW200806667A (en) | 2006-04-13 | 2008-02-01 | Astrazeneca Ab | New compounds |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| CN101460501A (zh) | 2006-06-05 | 2009-06-17 | 阿斯利康(瑞典)有限公司 | 作为髓过氧化物酶抑制剂的吡咯并[3，2-d]嘧啶-4-酮衍生物 |
| AR066936A1 (es) | 2007-06-13 | 2009-09-23 | Astrazeneca Ab | 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas. |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
-
2005
- 2005-12-02 MY MYPI20055659A patent/MY140748A/en unknown
- 2005-12-05 US US11/720,913 patent/US7829707B2/en active Active
- 2005-12-05 SA SA05260385A patent/SA05260385B1/ar unknown
- 2005-12-05 SI SI200631433T patent/SI1824855T1/sl unknown
- 2005-12-05 KR KR1020077012654A patent/KR101412786B1/ko active IP Right Grant
- 2005-12-05 KR KR1020137005332A patent/KR101412939B1/ko active IP Right Grant
- 2005-12-05 DK DK05812036.1T patent/DK1824855T3/da active
- 2005-12-05 WO PCT/SE2005/001835 patent/WO2006062465A1/en active Application Filing
- 2005-12-05 UA UAA200705136A patent/UA89968C2/uk unknown
- 2005-12-05 ME MEP-2012-109A patent/ME01486B/me unknown
- 2005-12-05 AU AU2005312388A patent/AU2005312388B2/en active Active
- 2005-12-05 BR BRPI0518846-6A patent/BRPI0518846B1/pt active IP Right Grant
- 2005-12-05 JP JP2007544307A patent/JP5028270B2/ja active Active
- 2005-12-05 RU RU2007119307/04A patent/RU2409578C2/ru active
- 2005-12-05 RS RS20120426A patent/RS52490B/en unknown
- 2005-12-05 AR ARP050105071A patent/AR051698A1/es unknown
- 2005-12-05 NZ NZ555046A patent/NZ555046A/en not_active IP Right Cessation
- 2005-12-05 EP EP05812036A patent/EP1824855B1/en active Active
- 2005-12-05 CA CA2591314A patent/CA2591314C/en active Active
- 2005-12-05 PT PT05812036T patent/PT1824855E/pt unknown
- 2005-12-05 RU RU2010139806/04A patent/RU2577858C2/ru active
- 2005-12-05 PL PL05812036T patent/PL1824855T3/pl unknown
- 2005-12-05 KR KR1020137033109A patent/KR101557715B1/ko active IP Right Grant
- 2005-12-05 ES ES05812036T patent/ES2390888T3/es active Active
- 2005-12-05 CN CN2005800419194A patent/CN101072778B/zh active Active
- 2005-12-05 UY UY29246A patent/UY29246A1/es not_active Application Discontinuation
- 2005-12-05 MX MX2007006497A patent/MX2007006497A/es active IP Right Grant
- 2005-12-06 TW TW094143007A patent/TWI365189B/zh not_active IP Right Cessation
-
2007
- 2007-05-10 NO NO20072399A patent/NO20072399L/no unknown
- 2007-05-14 IL IL183182A patent/IL183182A/en not_active IP Right Cessation
-
2008
- 2008-05-13 HK HK08105257.9A patent/HK1110859A1/xx unknown
-
2010
- 2010-11-03 US US12/938,490 patent/US8859568B2/en active Active
-
2012
- 2012-10-02 HR HRP20120781TT patent/HRP20120781T1/hr unknown
- 2012-10-10 CY CY20121100939T patent/CY1113209T1/el unknown
-
2014
- 2014-09-15 US US14/487,009 patent/US9580429B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051698A1 (es) | Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa | |
| AR120080A1 (es) | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos | |
| CO5140068A1 (es) | Nuevas composiciones de medicamentos a base de compuestos anticolinergicamente activos y -mimeticos | |
| AR035804A1 (es) | Inhibidores novedosos de tirosina cinasa | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR056197A1 (es) | Derivados de 7-metilimidazol[1,2-a]piridin-6-il-8-metil-nonamidas como inhibidores de la renina, composciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de la hipertension arterial | |
| AR076706A1 (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR061867A1 (es) | Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa | |
| HUP0303271A2 (hu) | Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására | |
| AR051388A1 (es) | Analogos de 17-hidroxiwortmanina como inhibidores de pi3k | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| PE20021010A1 (es) | Derivados espirociclicos como inhibidores de fosfodiesterasa-7 | |
| BRPI0517461A (pt) | compostos farmacêuticos | |
| AR045134A1 (es) | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic | |
| AR030188A1 (es) | Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos | |
| AR063869A1 (es) | Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante | |
| UY27503A1 (es) | Nuevos derivados de piperazina | |
| CL2007001711A1 (es) | Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras. | |
| AR054790A1 (es) | Metodos para el tratamiento de disfuncion sexual | |
| ECSP066349A (es) | Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales | |
| AR061015A1 (es) | Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |